David Morris, MD is a pediatric allergist and immunologist, and division chief of allergy and immunology at Dayton Children's Hospital. Dr. Morris was born and raised in the Dayton area. He completed his medical school education at Wright State University Boonshoft School of Medicine in Dayton, Ohio. Following college, he spent his internship and residency in pediatrics at Dayton Children's Hospital. He completed his fellowship in allergy and immunology at Cincinnati Children's Hospital Medical Center in Cincinnati, Ohio. Dr. Morris is board certified in both pediatrics and allergy and immunology. He has participated in multiple peer-reviewed articles and serves as an assistant professor in pediatrics at Wright State University Boonshoft School of Medicine. Dr. Morris was awarded an American Academy of Allergy, Asthma and Immunology Fellow-In-Training Grant in Characterization of Eosinophil Progenitors in the Peripheral Blood of Pediatric Patients with Active Eosinophilic Esophagitis (2014).
When asked why he chose to specialize in pediatric allergy and immunology, he said that it is because of the ever changing knowledge within the field that makes each day exciting. One of his favorite things about working with children is their spirit and resiliency in the face of adversity. Outside of the hospital, Dr. Morris enjoys activities with his children.
Scheduling in-person appointments for new patients only. For follow-up, second opinion or video visit appointments, please call 937-641-4000
education and training
- medical school: Wright State University Boonshoft School of Medicine, Dayton, Ohio
- internship: Dayton Children's Hospital
- residency: Pediatrics - Wright State University, Dayton Children’s Hospital, Dayton, Ohio
- fellowship: Allergy and Immunology - University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
- board certification: Pediatrics, allergy and immunology
awards, honors or organizations
Morris, David (PI), AAAAI Fellow-In-Training Grant, Characterization of Eosinophil Progenitors in the Peripheral Blood of Pediatric Patients with Active Eosinophilic Esophagitis. July 2014-July 2015
publications and presentations
- Schwartz, JT, Morris D, Collins MH, Rothenberg ME, Fulkerson PC; Eosinophil progenitor levels correlate with pathology in pediatric eosinophilic esophagitis, JACI (2019) Vol 143 (3), pages 1221-24
- Rosenberg CE, Mingler MK, Caldwell JM, Collins MH, Fulkerson PC, Morris D, Mukkada VA, Putnam PE, Shoda T, Wen T, Rothenberg, ME; Esophageal IgG4 Levels correlate with histopathic and transcriptomic features in eosinophilic esophagitis, Allergy (2018); 73:1892-1901
- Tuttle KL, Schneider TR, Henrickson S, Morris D, Abonia JP, Spergel J, Laidlaw T; Asprin-exacerbrated respiratory disease; not always "adult-onset", JACI: In Practice (2016) Vol. 4 (4) pages 756-758
- Morris D, Stucke E, Martin LJ, Abonia JP, Mukkada VA, Putnam PE, Rothenberg ME, Fulkerson P, Eosinophil progenitor levels are increased in active pediatric eosinophilic esophagitis, JACI (2016), 138 (3):915-918
- Miller RD, ......Morris D (44 of 63), High-density single-polymorphism maps of the human genome, Genomics (2005) August, 86 (2):117-26.
- Berberich SJ, Litteral V, Mayo LD, Tabesh D, Morris D, Mdm-2 Gene Amplification in 3T3L1 Preadipocytes, Differentiation (1999) May 64 (4):205-212.
clinical trial experience
- Compassionate Use Open-Label Study of Anti-IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome, Sub-Investigator, 2013-2016
- ARC: Oral Desnsitization to Peanut in Peanut-Allergic Children and Adults using Characterized Peanut Allergen (CPNA) Peanut Oral Immunotherapy (OIT) Safety Follow-On Study, Sub-Investigator, 2014-present
- A Double-Blind, Placebo-Controlled, Randomized Phase III Pivotal Trial to Assess the Efficacy and Safety of Peanut Epicutaneous Immunotherapy with ViaSkin(R) Peanut in Peanut-Allergic Children (PEPITES Study), Sub-Investigator, 2015-2016
- MTAX: A Phase 2 Study Multi Oral Immunotherapy in Multi Food allergic Patients to Test Tolerance, Sub-Investigator, 2015-present
- REGENERON Protocol R668-EE-1324: A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Dupilumab in Adult Patients with Active Eosinophilic Esophagitis, Sub-Investigator, 2015-present
- CEGIR 7802: SOFEED Study: Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) followed by Swallowed Glucocorticoid Trial, Sub-Investigator, 2015-present
- PCORI diet study: Eosinophilic Esophagitis (EoE) Intervention Trail-Randomized 1 Food Elimination vs. 4 Food Elimination Diet followed by Swallowed Glucocorticoids, Sub Investigators 2015-present
Allergic asthma, Allergic conjunctivitis, Allergic rhinitis, Anaphylaxis, Atopic dermatitis, Eczema, Eosinophilia, Food allergy, Hereditary angiodema, Hives, Insect sting allergy, Medication allergies, Primary Immune Deficiency, Urticaria and angioedema